Auxilium Pharmaceuticals (AUXL) Set to Announce Quarterly Earnings on Monday
Auxilium Pharmaceuticals (NASDAQ:AUXL) will issue its quarterly earnings data on Monday, May 5th. Persons that wish to listen to the company’s earnings conference call can do so using this link.
Auxilium Pharmaceuticals (NASDAQ:AUXL) last released its earnings data on Friday, February 28th. The company reported $0.27 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.22 by $0.05. The company had revenue of $125.90 million for the quarter, compared to the consensus estimate of $111.83 million. During the same quarter in the previous year, the company posted $1.83 earnings per share. The company’s revenue for the quarter was down 27.0% on a year-over-year basis. On average, analysts expect Auxilium Pharmaceuticals to post $0.27 EPS for the current fiscal year and $1.23 EPS for the next fiscal year.
Shares of Auxilium Pharmaceuticals (NASDAQ:AUXL) opened at 22.07 on Friday. Auxilium Pharmaceuticals has a one year low of $14.37 and a one year high of $32.89. The stock has a 50-day moving average of $27.33 and a 200-day moving average of $23.52. The company’s market cap is $1.094 billion.
A number of analysts have recently weighed in on AUXL shares. Analysts at UBS AG reiterated a “buy” rating on shares of Auxilium Pharmaceuticals in a research note on Wednesday. They now have a $31.00 price target on the stock. On the ratings front, analysts at RF Lafferty & Co. downgraded shares of Auxilium Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Wednesday. They now have a $19.00 price target on the stock. Finally, analysts at R. F. Lafferty downgraded shares of Auxilium Pharmaceuticals from a “buy” rating to a “neutral” rating in a research note on Wednesday. They now have a $19.00 price target on the stock. Two equities research analysts have rated the stock with a sell rating, five have assigned a hold rating and ten have assigned a buy rating to the company. Auxilium Pharmaceuticals presently has a consensus rating of “Hold” and a consensus price target of $27.88.
Auxilium Pharmaceuticals, Inc is a specialty biopharmaceutical company focuses on developing and marketing products to predominantly specialist audiences.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.